Trial reportDiabetes care2011
Effect of diacerein on insulin secretion and metabolic control in drug-naive patients with type 2 diabetes: a randomized clinical trial.
Trial report in Diabetes care, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 29 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Effect of Diacerein in the Metabolic Control of Patients With Diabetes Mellitus Type 2 and Secondary Failure to Metformin
Effect of Diacerein in the Metabolic Control of Patients With Diabetes Mellitus Type 2 and Secondary Failure to Metformin
Who cites it
29 citing papers in PubMed, 3 syntheses or guidelines pooled it, 68 citations in OpenAlex.
- Effects of anti-inflammatory therapies on glycemic control in type 2 diabetes mellitus.Frontiers in immunology · 2023Pooled it
- Looking for Crumbs in the Obesity Forest: Anti-obesity Interventions and Obesity-Associated Cardiometabolic Traits in the Mexican Population. History and Systematic Review With Meta-Analyses.Frontiers in medicine · 2021Pooled it
- The Effect of Diacerein on Type 2 Diabetic Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with Trial Sequential Analysis.Journal of diabetes research · 2020Pooled it
- The glucose-lowering effect of low-dose diacerein and its responsiveness metabolic markers in uncontrolled diabetes.BMC research notes · 2022Trial
- Effect of Diacerein on Metabolic Control and Inflammatory Markers in Patients with Type 2 Diabetes Using Antidiabetic Agents: A Randomized Controlled Trial.Journal of diabetes research · 2018Trial
- Trial
- Beneficial effects of Korean traditional diets in hypertensive and type 2 diabetic patients.Journal of medicinal food · 2014Trial
- Effect of avocado soybean unsaponifiables on insulin secretion and insulin sensitivity in patients with obesity.Obesity facts · 2013Trial
- Effect of diacerein as an add-on to metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.Archives of endocrinology and metabolismTrial
- Diacerein improves liver fibrosis, steatosis, and atherosclerosis in ApoE knockout mice.Journal of molecular medicine (Berlin, Germany) · 2026Article
- Emodin and the Anthraquinone Scaffold: Therapeutic Promise and Strategies to Overcome Translational Barriers.Molecules (Basel, Switzerland) · 2026Review
- Molecular and pathophysiological relationship between obesity and chronic inflammation in the manifestation of metabolic dysfunctions and their inflammation‑mediating treatment options (Review).Molecular medicine reports · 2024Review
- Anti-Inflammatory and Anti-Adipocyte Dysfunction Effects ofPharmaceuticals (Basel, Switzerland) · 2024Article
- Insights on the role of anti-inflammatory and immunosuppressive agents in the amelioration of diabetes.Diabetology international · 2023Review
- Inflammation in obesity, diabetes, and related disorders.Immunity · 2022Review
- Impaired macrophages and failure of steroidogenesis and spermatogenesis in rat testes with cytokines deficiency induced by diacerein.Histochemistry and cell biology · 2021Article
- The association between serum interleukin-1 beta and heparin sulphate in diabetic nephropathy patients.Glycoconjugate journal · 2021Article
- An Update of Anthraquinone Derivatives Emodin, Diacerein, and Catenarin in Diabetes.Evidence-based complementary and alternative medicine : eCAM · 2021Review
- Mesenchymal stem cells ameliorate β cell dysfunction of human type 2 diabetic islets by reversing β cell dedifferentiation.EBioMedicine · 2020Article
- The Role of Inflammation in Diabetes: Current Concepts and Future Perspectives.European cardiology · 2019Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
objectiveTo assess the effect of diacerein on insulin secretion and metabolic control in drug-naïve patients with type 2 diabetes. RESEARCH DESIGN AND
methodsA randomized, double-blind, placebo-controlled clinical trial was carried out in 40 drug-naïve adult patients with type 2 diabetes. A metabolic profile including interleukin (IL)-1β, tumor necrosis factor-α, IL-6, and fasting insulin levels was carried out before the intervention and 2 months afterward. A hyperglycemic-hyperinsulinemic clamp technique was performed to assess the phases of insulin secretion and insulin sensitivity. After randomization, 20 patients received diacerein (50 mg once daily) for the first 15 days and twice daily for 45 additional days. The remaining patients received placebo. Intra- and intergroup differences were calculated by Wilcoxon signed rank and Mann-Whitney U tests.
resultsThere were significant increases in first (102±63 vs. 130±75 pmol/L; P<0.01), late (219±111 vs. 280±135 pmol/L; P<0.01), and total insulin (178±91 vs. 216±99 pmol/L; P<0.01) secretions without changes in insulin sensitivity after diacerein administration. There were significant decreases in fasting glucose (7.9±1.4 vs. 6.8±1.0 mmol/L; P<0.01) and in A1C levels (8.3±1.0 vs. 7.0±0.8%; P<0.001) after diacerein administration. There were no significant changes after placebo administration in the above-mentioned evaluations.
conclusionsInsulin secretion increased and metabolic control improved after diacerein administration in drug-naïve patients with type 2 diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.